Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Moleculin presented pooled cardiac safety data for Annamycin at ASCO 2026, showing no detectable cardiotoxicity in 90 patients across five completed trials. The analysis covered cumulative doses up to 2,970 mg/m², far exceeding conventional anthracycline limits, with independent validation from Cleveland Clinic cardiology specialists.
Key figures
- Drug Name
- Annamycin (naxtarubicin)
- Phase Of Trial
- Phase 2b/3
- Aml cr rate pct
- 50
- Aml crc rate pct
- 60
- Aml median os months
- 12.39
- Patients with lvef data
- 78
- Lvef mean difference pct
- -0.12
- Pooled analysis patients
- 90
- Max cumulative dose mg m2
- 2970
- Median cumulative dose mg m2
- 660
- Aml transplant rate among responders pct
- 50
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.